Tweetovi

Blokirali ste korisnika/cu @VerveTx

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @VerveTx

  1. 23. sij

    We love having our own lab at 215 First Street — take a peek inside our new space.

    Poništi
  2. 22. sij

    Make 2020 the year you use your skills to join the fight against the leading cause of death worldwide: Verve is hiring for a number of roles on the front lines of creating gene-editing therapies to treat heart disease. Explore our openings:

    Poništi
  3. 21. sij

    An important piece by and analyzing why cardiovascular death rates are rising, even in places where they’ve been historically low. Take a read:

    Poništi
  4. 17. sij

    We had a wonderful time last night celebrating the holidays with colleagues, family members, and the extended Verve team!

    Poništi
  5. 9. sij

    As we enter 2020, we’re sobered by the knowledge that will claim millions of lives in the year ahead. Learn more about heart disease and our vision to develop a new treatment approach using gene editing:

    Poništi
  6. 31. pro 2019.

    2019 has been momentous. We've grown to 25 employees, moved to Kendall Square, and advanced our gene editing programs for heart disease. We're looking forward to an equally exciting 2020! Wishing everyone a happy and healthy new year!

    Poništi
  7. 20. pro 2019.

    Happy holidays from all of us at !

    Poništi
  8. 16. pro 2019.

    there are people with naturally occurring genetic mutations that lower LDL cholesterol and protect them against heart disease. We are developing gene-editing therapies that mimic these same protective mutations to prevent heart disease. Learn more:

    Poništi
  9. 11. pro 2019.

    We've moved! The team is settling into our new space in Kendall Square, with a state-of-the-art lab and office all under one roof. Looking forward to a new year in our new space!

    Poništi
  10. 5. pro 2019.

    We want to thank Beam Therapeutics for hosting us in their office this year and for the lovely going away celebration. We’re packing up and moving to our new space on Monday!

    Poništi
  11. 28. stu 2019.
    Poništi
  12. 25. stu 2019.

    What's in a name? We believe that tackling heart disease — a leading cause of death globally — requires the deep passion & drive that are inherent in "verve." Verve is also in our vision: a future of vitality & vigor for people at risk of heart disease.

    Poništi
  13. 21. stu 2019.

    Many people have high genetic risk for , even after carefully managing other risk factors like diet, exercise & smoking. Our mission is to create a one-time therapy that could permanently & safely reduce risk factors in adults. Learn more:

    Poništi
  14. 18. stu 2019.

    The team had a productive time seeing friends and making new connections at in Philadelphia. Verve is developing gene editing therapies for adults at high risk of heart disease and heart attack.

    Poništi
  15. 18. stu 2019.

    Congrats to 's Alexandra Chadwick, Ph.D., associate director, preclinical research and development, who will present on gene editing as a therapeutic approach for cardiovascular disease Scientific Sessions

    Poništi
  16. 15. stu 2019.

    Looking forward to catching up with colleagues and discussing the future of cardiovascular medicine at Scientific Sessions this weekend.

    Poništi
  17. 12. stu 2019.

    The team is growing, and we’re enjoying getting to know our new friends and colleagues outside of work!

    Poništi
  18. 7. stu 2019.

    Dr. Kiran Musunuru, Verve co-founder & senior scientific advisor, is an associate professor of cardiovascular medicine & genetics at where he has made outstanding research contributions in gene editing to study and treat . Read more:

    Poništi
  19. 1. stu 2019.

    We are hiring! If you share our vision to develop gene editing therapies to treat heart disease, check out our open positions for Principal/Senior Scientist, In Vivo Pharmacology and Associate Scientist, In Vivo Pharmacology.

    Poništi
  20. 22. lis 2019.

    Congrats to Verve scientific advisory board member Dr. Daniel Rader and colleagues for their work to better diagnose patients with rare hereditary forms of high cholesterol. Learn more:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·